整合素α5与上皮性卵巢癌的相关性研究

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (575 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression of integrin α5 in epithelial ovarian tumors and to analyze its clinicopathological relationship with epithelial ovarian cancer. Methods From January 2015 to December 2017, Ovarian tumor tissue were collected from 80 hospitalized patients under the care of the Gynecology Center of the Qingdao Municipal Hospital (40 epithelial ovarian cancer samples, 20 borderline epithelial tumor samples and 20 benign epithelial tumor samples). Immunohistochemistry was used to detect the expression of integrin α5 protein in ovarian tumor tissues. Results The positivity of integrin α5 in epithelial ovarian cancer samples was 80.00% (32/40), which was significantly higher than that in borderline epithelial tumor samples (40.00% [8/20]) and benign epithelial tumor samples (20.00% [4/20])(P ＜ 0.01). There was no statistically significant difference in the positive expression rate of integrin α5 protein in epithelial ovarian cancer among different ages and pathological types (P > 0.05). There was a significant difference among different degree of pathological differentiation and different stages of operation and pathology (P ＜ 0.05); the difference was highly statistically significant between the presence and absence of lymph node metastasis (P ＜ 0.01). Spearman rank correlation analysis showed that the expression of integrin α5 in epithelial ovarian cancer tissues was significantly positively correlated with the surgical pathological stage, pathological differentiation degree and presence or absence of lymph node metastasis of ovarian cancer (r = 0.854, 0.765, 0.895, P ＜ 0.05). Conclusion The overexpression of integrin α5 in epithelial ovarian cancer tissues is closely related to the degree of pathological differentiation, surgical pathological stage and lymph node metastasis. Monitoring the expression of integrin α5 may help to determine the long-term prognosis of ovarian cancer patients and guide clinical treatment.

Key words： Integrin α5 Ovarian tumor Epithelial ovarian cancer Immunohistochemistry

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MU Xiang1 DU Weimin1 SHI Kexin2 ZHANG Yumin3 ZHANG Ping1

Cite this article:

MU Xiang1 DU Weimin1 SHI Kexin2 ZHANG Yumin3 ZHANG Ping1. Correlation between integrin α5 and epithelial ovarian cancer[J]. 中国医药导报, 2020, 17(14): 114-117.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I14/114

[1] Prat J. New insights into ovarian cancer pathology [J]. Ann Oncol，2012，23（10）：111-117.
[2] Zhang L，Zou W. Inhibition of integrin beta1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway [J]. Mol Med Rep，2015，12（6）：7869-7876.
[3] 徐丛剑，华克勤.实用妇产科学[M].4版.北京：人民卫生出版社，2018：651.
[4] Sawada K，Mitra AK，Radjabi AR，et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin，which is a therapeutic target [J]. Cancer Res，2008，68（7）：2329-2339.
[5] Raab-Westphal S，Marshall JF，Goodman SL. Integrins as Therapeutic Targets：Successes and Cancers [J]. Cancers （Basel），2017，9（9）：110.
[6] Li Y，Xiao Y，Lin HP，et al. In vivo beta-catenin attenuation by the integrin alpha5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis [J]. Biomaterials，2019，188：160-172.
[7] Guo L，Fu J，Sun S，et al. MicroRNA-143-3p inhibits colorectal cancer metastases by targeting ITGA6 and ASAP3 [J]. Cancer Sci，2019，110（2）：805-816.
[8] Zhang L，Zhang T，Deng Z，et al. MicroRNA-3653 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting ITGB1 [J]. Oncol Rep，2019，41（3）：1549-1559.
[9] 龙志国，朱红波，李凯.食管鳞状细胞癌中整合素α3β1及基质金属蛋白酶-7的表达及生物学意义[J].中国医药导报，2013，10（11）：29-30.
[10] Chen JP，Huang QD，Wan T，et al. Combined score of pretreatment platelet count and CA125 level （PLT-CA125） stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer [J]. J Ovarian Res，2019，12（1）：72.
[11] 《肿瘤病理诊断规范》项目组.肿瘤病理诊断规范（卵巢癌及交界性上皮性肿瘤）[J].中华病理学杂志，2018，47（5）：324-327.
[12] Rajeswari J，Pande G. The significance of alpha 5 beta 1 integrin dependent and independent actin cytoskelton organization in cell transformation and survival [J]. Cell Biol Int，2002，26（12）：1043-1055.
[13] Giancotti FG，Ruoslahti E. Integrin signaling [J]. Science，1999，285（5430）：1028-1032.
[14] Hamidi H，Ivaska J. Every step of the way：integrins in cancer progression and metastasis [J]. Nat Rev Cancer，2018，18（9）：533-548.
[15] Chan JK，Teoh D，Hu JM，et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers [J]. Gynecol Oncol，2008，109（3）：370-376.
[16] Xiao Y，Li Y，Tao H，et al. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway [J]. Cancer Lett，2018（433）：199-209.
[17] Zutter MM，Mazoujian G，Santoro SA. Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast [J]. Am J Pathol，1990，137（4）：863-870.
[18] Lu L，Xie R，Rong W，et al. Integrin α5 subunit is required for the tumor supportive role of fibroblasts in colorectal adenocarcinoma and serves as a potential stroma prognostic marker [J]. Mol Oncol，2019，13（12）：2697-2714.
[19] 向小芳，杨桂芳，杨倩.整合素α5β1和血管内皮生长因子在结直肠癌中的表达及临床意义[J].中华实验外科杂志，2012，29（2）：119-201.
[20] Pelillo C，Mollica H，Eble JA，et al. Inhibition of adhesion，migration and of alpha5beta1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A [J]. J Inorg Biochem，2016，160：225-235.